These Are The 10 Top Holdings Of Fred Knoll| MENAFN.COM

Friday, 20 May 2022 10:48 GMT

These Are The 10 Top Holdings Of Fred Knoll


(MENAFN- ValueWalk) JESHOOTS-com / Pixabay

Fred Knoll is the founder of Knoll Capital Management. He has been leading the investment management firm since he founded it in 1987. Knoll has studied at M.I.T. and did his MBA from Columbia University. He previously worked for Telos Corporation, Murray Johnstone, Robert Fleming and General American Investors. Currently, Knoll has made significant investments in biotech companies. Let's take a look at the ten top holdings of Fred Knoll.

Get The Full Henry Singleton Series in PDF

Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q4 2021 hedge fund letters, conferences and more

Gates Capital Returns 32.7% Tries To Do“Fewer Things Better”

Gates Capital Management's Excess Cash Flow (ECF) Value Funds have returned 14.5% net over the past 25 years, and in 2021, the fund manager continued to outperform. Due to an 'absence of large mistakes' during the year, coupled with an 'attractive environment for corporate events,' the group's flagship ECF Value Fund, L.P returned 32.7% last Read More

Table of Contents show
  • 1. Top Ten Holdings Of Fred Knoll
  • 2. Blackstone
  • 3. Abeona Therapeutics
  • 4. Anavex Life Sciences
  • 5. Eiger BioPharmaceuticals
  • 6. Aldeyra Therapeutics
  • 7. Corbus Pharmaceuticals Holdings
  • 8. Orgenesis
  • 9. Entera Bio
  • 10. Applied Therapeutics
  • 11. Biohaven Pharmaceutical Holding
Top Ten Holdings Of Fred Knoll

We have referred to the latest 13F filing (September 30, 2021) of Knoll Capital Management to come up with the top ten holdings of Fred Knoll. Following are the top ten holdings of Fred Knoll:

  • Blackstone
  • Founded in 1985 and headquartered in New York, this company offers investment and fund management services. Knoll owns 24,000 shares of Blackstone Inc (NYSE:BX) at an average estimated price of $34.97. These shares have a market value of more than $2.79 million and account for 1.39% of Knoll's portfolio. Blackstone shares are down almost 12% YTD and almost 8% in the last three months.

  • Abeona Therapeutics
  • Founded in 1974 and headquartered in New York, this company develops gene therapy for severe and life-threatening rare diseases. Knoll owns more than 2.8 million shares of Abeona Therapeutics Inc (NASDAQ:ABEO) at an average estimated price of $4.53. These shares have a market value of more than $3.20 million and account for 1.60% of Knoll's portfolio. Abeona Therapeutics shares are down almost 23% YTD and almost 71% in the last three months.

  • Anavex Life Sciences
  • Founded in 2004 and headquartered in New York, it is a clinical stage biopharmaceutical firm that focuses on neurodegenerative and neurodevelopmental diseases. Knoll owns 210,789 shares of Anavex Life Sciences Corp (NASDAQ:AVXL) at an average estimated price of $4.07. These shares have a market value of more than $3.78 million and account for 1.89% of Knoll's portfolio. Anavex Life Sciences shares are down almost 24% YTD and over 26% in the last three months.

  • Eiger BioPharmaceuticals
  • Founded in 2008 and headquartered in Palo Alto, Calif., this company develops and commercializes foundational therapies for the Hepatitis Delta Virus. Knoll owns 694,232 shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) at an average estimated price of $9.75. These shares have a market value of more than $4.63 million and account for 2.31% of Knoll's portfolio. Eiger BioPharmaceuticals shares are down almost 18% YTD and almost 33% in the last three months.

  • Aldeyra Therapeutics
  • Founded in 2004 and headquartered in Lexington, Mass., it is a biotechnology company. Knoll owns 569,405 shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) at an average estimated price of $11.82. These shares have a market value of almost $5 million and account for 2.49% of Knoll's portfolio. Aldeyra Therapeutics shares are down almost 13% YTD and over 57% in the last three months.

  • Corbus Pharmaceuticals Holdings
  • Founded in 2009 and headquartered in Norwood, Mass., it is a phase 3 clinical-stage pharmaceutical company. Knoll owns more than 5.04 million shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) at an average estimated price of $4.99. These shares have a market value of more than $5 million and account for 2.57% of Knoll's portfolio. Corbus Pharmaceuticals shares are down almost 19% YTD and almost 51% in the last three months.

  • Orgenesis
  • Founded in 2008 and headquartered in Germantown, Md., it is a biotechnology company that focuses on cell and gene therapy. Knoll owns more than 1.31 million shares of Orgenesis Inc (NASDAQ:ORGS) at an average estimated price of $6.08. These shares have a market value of more than $6.51 million and account for 3.25% of Knoll's portfolio. Orgenesis shares are down almost 15% YTD and over 48% in the last three months.

  • Entera Bio
  • Founded in 2010 and headquartered in Jerusalem, Israel, this company develops and commercializes orally delivered large molecule therapeutics. Knoll owns more than 2.48 million shares of Entera Bio Ltd (NASDAQ:ENTX) at an average estimated price of $4.04. These shares have a market value of more than $11 million and account for 5.84% of Knoll's portfolio. Entera Bio shares are up almost 1% YTD but are down over 35% in the last three months.

  • Applied Therapeutics
  • Founded in 2016 and headquartered in New York, it is a clinical-stage biopharmaceutical firm. Knoll owns more than 1.03 million shares of Applied Therapeutics Inc (NASDAQ:APLT) at an average estimated price of $17.04. These shares have a market value of more than $17 million and account for 8.54% of Knoll's portfolio. Applied Therapeutics shares are down over 58% YTD and almost 78% in the last three months.

  • Biohaven Pharmaceutical Holding
  • Founded in 2013 and headquartered in New Haven, Conn., it is also a clinical-stage biopharmaceutical company. Knoll owns 856,844 shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) at an average estimated price of $27.10. These shares have a market value of more than $119 million and account for 59.36% of Knoll's portfolio. Biohaven Pharmaceutical shares are down over 14% YTD and over 10% in the last three months.

    Updated on Jan 19, 2022, 9:57 am

    MENAFN19012022005205011743ID1103564958


    Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.